Amphastar Pharmaceuticals faces regulatory scrutiny after a subsidiary received an FDA warning over manufacturing violations at a California facility.
Amphastar Pharmaceuticals (AMPH) shares fell in premarket trading after the company revealed its subsidiary, International Medication Systems, received an FDA warning letter. The letter cited manufacturing-related violations at a California facility, raising compliance concerns for the drugmaker.
The warning follows routine inspections and could lead to corrective actions or further regulatory scrutiny. Amphastar has not disclosed the specific violations or potential financial impact. The stock decline reflects investor caution over regulatory risks in the pharmaceutical sector.
Premarket trading showed AMPH down, though broader market movements were limited. The FDA’s action may prompt operational reviews or delays in product approvals if unresolved.